Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With <i>ERBB2</i> Amplification or <i>ERBB2/3</i> Mutations: Results From the TAPUR Study.
Ranju GuptaFunda Meric-BernstamMichael RotheElizabeth Garrett-MayerPam K MangatStacy D'AndreEugene R AhnRaegan O'LoneSusan HalabiGina N GranthamRichard L SchilskyPublished in: JCO precision oncology (2022)
Although P + T treatment does not appear to have antitumor activity in CRC with <i>ERBB2/3</i> mutations, this combination has antitumor activity in patients with CRC with <i>ERBB2</i> amplification and warrants further study.